Summary nm23 gene expression has been shown to be inversely correlated with tumour metastatic potential in some cancers but not in others. Examination was made of the expression of nm23-HI and nm23-H2 gene products by immunohistochemistry and immunoblotting in 28 endomentrial carcinomas. Immunohistochemistry indicated the cytoplasm of cancer cells to be positive, and myometrium and endometrial stromal cells negative, for nm23-Hl and -H2 protein. The staining intensity for these proteins was significantly stronger in well-differentiated adenocarcinomas (GI) than in those moderately differentiated (G2) (P<0.05). nm23-HI and -H2 proteins were shown by immunoblotting to be present at significantly higher levels in GI than in G2 tumours (P<0.05). Two of eight cases expressed high nm23-Hl and -H2 protein in poorly differentiated adenocarcinomas (G3). In G3 tumours, nm23 expression may be diverse. In this study, the expression of nm23-H1 and -H2 was not correlated with stage, metastasis, tumour size, myometrial invasion, oestrogen receptor, progesterone receptor or menopause. It follows from the findings presented above that the high expression of nm23-H1 and -H2 is positively correlated with histological differentiation.
The nm23 gene has been shown to be a metastasis-suppressor gene by differential hybridisation between two murine melanoma sublines, one with high and the other with low metastatic potential (Steeg et al., 1988) . The deduced amino acid sequence of the human nm23 gene shares 78% homology with that of the Drosophila abnormal wing disc (awd) gene (Rosengard et al., 1989) . The gene product is nucleoside diphosphate (NDP) kinase, which is essential for maintaining nucleoside triphosphate (NTP) pools in cells (Kimura et al., 1990; Wallet et al., 1990) . There are two isoforms of the human nm23 gene, nm23-H1 and nm23-H2 (Stahl et al., 1991) . nm23-HI and nm23-H2 have been shown to be identical respectively, to NDP kinases A and B from human erythrocytes (Gilles et al., 1991) .
The reduced expression of nm23 mRNA and protein is associated with increased metastatic ability of human breast carcinomas (Bevilacqua et al., 1989; Hennessy et al., 1991; Hirayama et al., 1991; Royds et al., 1993) . When the nm23 cDNA is transfected into a metastatic murine melanoma cell line expressing low levels of this particular gene, transfected clones expressing the exogeneously induced nm23 gene show significantly reduced in vivo metastatic potential . However, studies on colon carcinoma or neuroblastoma indicate increased nm23 gene expression to be associated with advanced stages of the disease (Hailat et al., 1991; Leone et al., 1993; Myeroff and Markowitz, 1993) . Correlations between nm23 expression and metastatic potential would thus appear to depend on specific cancers.
Endometrial carcinoma is the most prevalent neoplasm of the female pelvis and has been detected in patients under the age of 45 (Jeffery et al., 1987) . There is no report on the expression of nm23 in endometrial carcinoma. Thus, in this study, examination was made of the expression of nm23-HI and nm23-H2 in endometrial carcinomas by immunohistochemical and immunoblotting methods to clarify the association of nm23 expression with tumour metastatic potential, degree of (FIGO, 1989) . There were 15 well-differentiated (GI), five moderately differentiated (G2) and eight poorly differentiated adenocarcinomas (G3) and two leiomyosarcomas of the uterine corpus. Patient age ranged from 36 to 80 years, the median being 57 years. ER and PR in tumour tissue freshly obtained at surgery were measured by the radioreceptor assay system of Kitasato Biochemical Laboratory, Kanagawa, Japan. A tissue sample (0.5 cm3) was also obtained and processed by AMeX, as described below.
AMeX procedure Sato et al. (1986, 1992) devised the AMeX (acetone, methylbenzoate, xylene) procedure for tissue processing and paraffin embedding before haematoxylin-eosin staining, immunostaining and immunoblotting. Morphological preservation of sections prepared by this method is consistently better than that of frozen sections and similar to that of routinely formalin-fixed paraffin sections. Proteins extracted from AMeX-processed tissue can be applied to immunoblotting. The technique is very simple for general clinical laboratory use, and paraffin blocks fixed by this method can be stored at 4C for future study. Immunohistochemistry and immunoblotting were performed on the specimens obtained from the same block.
Immunohistochemistry
Two mouse monoclonal antibodies (MAb), H1-229 (MAb for nm23-HI) and H2-439 (MAb for nm23-H2), were kindly provided by Dr Shiku, Department of Oncology, Nagasaki University, Nagasaki, Japan (Urano et al., 1993) . Paraffinembedded samples were sectioned at 4 ytm and deparaffinised with Histo-Clear (National Diagnostics, Atlanta, GA, USA). They were then immediately immersed in 4% paraformaldehyde for 5 min and washed with phosphate-buffered saline (PBS 0.0075 M pH 7.4). Immunohistochemical staining was carried out by the avidin-biotin-peroxidase complex (ABC) method. In brief, the sections were incubated with 2% normal swine serum and then with H1-229 (2 tgml-') or H2-439 (4 pg ml-') overnight at room temperature, rinsed with PBS and incubated with biotinylated anti-mouse IgG (200-fold diluted, Vector, Burlingame, CA, USA) for 30 min. This was followed by reaction in 0.3% hydrogen peroxide in methanol for 30 min and then ABC and diaminobenzidine reactions. Nuclear counterstaining was done using Mayer's haematoxylin solution. As negative controls, sections were stained by replacing the primary antibody with normal mouse serum at the same IgG concentration. Immunostaining intensity was categorized as strongly positive (+ +), positive (+) or negative (-) in comparison with background intensity.
Immunoblotting Sections of cancer area were selectively cut from AMeXprocessed tissue. They were deparaffinised with xylene and washed by centrifugation in acetone. All specimens were resuspended in Laemmli's sample buffer (Laemmli, 1970) by brief sonication and diluted to 4 mg protein ml-'. Lysates of 10 LI (40 jig of protein) were heated at 100°C for 3 min and loaded onto a 15% SDS-polyacrylamide gel, which was then transferred to a nylon membrane (Immobilon-P, Millipore). The membrane was incubated with Block Ace (Dainihon Seiyaku, Suita, Osaka, Japan) and then with H1-229 (2 jig ml-') or H2-439 (2 g m -1) for h, rinsed with PBS containing 0.3% Tween (PBS-T). This was followed by incubation with peroxidase-labelled anti-mouse IgG (1000-fold diluted, Dako, Kyoto, Japan) for 1 h. A band was detected on exposed X-ray film by a Western blot chemiluminescence reagent (DuPont, Boston, MA, USA Mean relative values of tumour nm23-H1 and -H2 protein in comparison with the positive controls, i.e. NS-HI-9 and NS-H2-1 cell lysates, were 0.7 ± 0.4 and 0.7 ± 0.5 in GI, 0.2 ± 0.2 and 0.2 ± 0.2 in G2 and 0.6 ± 0.4 and 0.5 ± 0.4 in G3. The values for nm23-H1 and -H2 were significantly higher in GI than in G2 (P <0.05) (Table II) .
Discussion
In this study, assessment was made of the expression of nm23-H and nm23-H2 protein in endometrial carcinomas processed by the AMeX method (Sato et al., 1986 (Sato et al., , 1992 , in conjunction with immunohistochemical staining and immunoblotting. Agreement rates of the estimation of nm23-HI and -H2 protein expression by immunostaining and immunoblotting were 69% and 66%. In disagreement cases, immunohistochemical analysis tended to be estimated as higher than immunoblotting, possibly owing to subjective estimation in immunostaining. It thus follows that it is more accurate to determine the localisation of nm23 protein expression by immunostaining and nm23 protein levels by immunoblotting.
No correlation could be detected between the expression of nm23-Hl and -H2 protein and putative prognostic factors such as stage, metastatic potential, tumour size, myometrial invasion, ER, PR and menopause. The reduced expression of nm23 mRNA and protein is associated with increased metastatic potential in human breast (Bevilacqua et al., 1989; Hennessy et al., 1991; Hirayama et al., 1991; Royds et al., 1993) , hepatocellular (Nakayama et al., 1992), gastric carcinomas (Nakayama et al., 1993) and malignant melanoma (Fl0renes et al., 1992) . Increased nm23 expression has been shown to be associated with advanced stages of colon carcinoma (Myeroff and Markowitz, 1993) and neuroblastoma (Hailat et al., 1991; Leone et al., 1993) . No relationship between nm23 protein expression and clinicopathological factors has been demonstrated in breast (Sastre-Garau et al., 1992; Sawan et al., 1994) and pulmonary carcinoma (Higashiyama et al., 1992) . nm23-, (analogous to human nm23-H 1) and nm23-a (analogous to human nm23-H2) expression differs according to the organ in rat (Kimura et al., 1990; Shimada et al., 1993 and NS-H2-1 cell lines. *P <0.05, significant (Mann-Whitney U-test); NS, not significant. GI, well-differentiated adenocarcinoma; G2, moderately differentiated adenocarcinoma; G3, poorly differentiated adenocarcinoma; Stage, new FIGO classification. ER, oestrogen receptor; PR, progesterone receptor; +, positive; -, negative; pre, premenopause; post, post-menopause.
any metastatic enhancer/suppressor function of nm23 may be tumour specific and/or the mechanism for nm23 expression may differ according to biochemical conditions. The intensity of immunostaining of nm23-H1 and -H2 was significantly stronger in GI than in G2 (P<0.05). nm23-HI and -H2 protein were present significantly (P<0.05) more in GI than in G2 according to immunoblotting analysis. Strong and weak intensity in G3 was apparent by immunostaining. The high content of nm23-Hl and -H2 protein would thus appear associated with the high degree of differentiation of endometrial carcinomas, while there may be two types of poorly differentiated endometrial adenocarcinomas. Confirmation of this will require study on a greater number of cases. nm23 mRNA and protein are expressed more in well-differentiated tumours of human breast cancer (Hennessy et al., 1991; Royds et al., 1993) . Intense immunostaining of nm23-HI in human prostate cancer has been detected more often in poorly differentiated than moderately differentiated types (Igawa et al., 1994) . The tissue-and developmental phase-specific expression of nm23 gene (awd gene) in Drosophila has been observed (Timmons et al., 1993) . The expression of nm23 may depend on primary sites and their differentiation.
nm23-H2 protein has been identified as the human c-myc transcription factor PuF, thus showing a relationship between nm23-H2 and c-myc oncogene expression and suggesting nm23-H2 protein to be essential to transcriptional activation of the c-myc gene (Postel et al., 1993) . The inverse relation between c-myc expression and cell differentiation is well documented (Spencer and Groudine, 1991) and nm23 has been shown to inhibit the differentiation of mouse myeloid leukaemia cells (Okabe-Kado et al., 1992) . The elevated expression of nm23 is associated with N-myc amplification in advanced stages of human neuroblastomas (Hailat et al., 1991; Leone et al., 1993) . The mechanism for nm23 expression in well-differentiated tumours is still unknown. Poorly differentiated endometrial carcinomas highly expressing nm23-H2 may be independent of oestrogens and associated with c-myc overexpression.
In future study, clarification should be made of qualitative and quantitative relations between nm23-H2 and c-myc expression in endometrial carcinomas. It should also be determined whether nm23-H1 and -H2 have specific roles in tumour differentiation and if there are actually two types of endometrial carcinomas which express nm23 protein to different degrees.
